Abstract
Summary
Global Orthopedic Biomaterial Market Forecast till 2027
Market Overview
The global orthopedic biomaterials market is estimated to record the highest CAGR of 10. 5% during the review period, to surpass USD 40,519.52 million by 2027.
Orthopedic biomaterials are embedded in the human body as constituents. These gadgets are intended to play out certain organic capacities by subbing or fixing various tissues like bone, ligament, or tendons and ligaments and surprisingly directing bone fix when important.
The development of the orthopedic biomaterials market is driven by variables, for example, the developing interest in cutting-edge orthopedic biomaterials and the expanding pervasiveness of orthopedic sicknesses. Moreover, the expanding commonness of constant sicknesses sets out rewarding freedom for the market. Notwithstanding, the absence of repayment and a questionable administrative structure are probably going to limit the market development. Additionally, the global market is propelled by the increasing older population leading to an increase in the patient population and growing demand for next-generation orthopedic biomaterials
Market Segmentation
The global orthopedic biomaterials market is classified in terms of product, material class, application, and end-user.
By Product type, the global market has been segmented into Reconstructive Joint Replacements, Spinal Implants, Dental Implants, Trauma, Orthobiologics, and others.
Based on Material Class the market is subdivided into Metal and Non-Metal.
By Application, the market is further classified into Joint Replacement, Fracture Fixation, Tissue Fixation, Tissue Fixation, Implant Surgery, and Viscosupplementation.
By End User segment the market is segregated into Hospitals & Clinics, Ambulatory Surgical Centers, and Others.
Regional Analysis
Americas:
The Americas ruled the orthopedic biomaterials market in 2019 and is probably going to keep during the appraisal time frame too. This can be credited to the high commonness of orthopedic illnesses, item dispatches, and innovative progression around here. The appeal for orthopedic biomaterials and the satisfactory accessibility of talented experts in the locale are relied upon to fuel the local market development. The developing older populace is additionally bringing about the development of the orthopedic biomaterials market in the Americas. According to the Administration for Community Living, in the Americas, throughout the most recent ten years, the populace matured 65 and overdeveloped from 37.2 million out of 2006 to 49.2 million out of 2016.
Europe stood firm on the second-biggest footing in the orthopedic biomaterials market in 2019 and is expected to observe critical development over the gauge time frame because of a bigger number of patients and the accessibility of items in the area.
The Asia-Pacific is expected to record the most elevated development rate during the conjecture period.
The orthopedic biomaterials market in the Middle East and Africa has been filling consistently as of late. The key variables pushing the development of the orthopedic market are expanding the pervasiveness of orthopedics issues and subsidizing by private players and government bodies.
Major Players
The Key Companies Covered in the global orthopedic biomaterials Report are Stryker (US), CoorsTek Inc. (US), Zimmer Biomet Holdings Inc. (US), Institut Straumann AG (Switzerland), Kyocera Corporation (Japan), Smith & Nephew plc (UK), 3M (US), Nobel Biocare Services AG(Switzerland), Medtronicplc (Ireland), and DePuy Synthes (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
1 EXECUTIVE SUMMARY 22
1.1 OVERVIEW 22
1.1.1 MARKET SYNOPSIS 22
2 MARKET INTRODUCTION 23
2.1 SCOPE OF THE STUDY 23
2.2 RESEARCH OBJECTIVE 23
2.3 LIST OF ASSUMPTIONS & LIMITATIONS 23
3 RESEARCH METHODOLOGY 25
3.1 OVERVIEW 25
3.2 DATA MINING 25
3.3 SECONDARY RESEARCH 26
3.4 PRIMARY RESEARCH 27
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 27
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 28
3.5 FORECASTING TECHNIQUES 29
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30
3.6.1 BOTTOM-UP APPROACH 31
3.6.2 TOP-DOWN APPROACH 31
3.7 DATA TRIANGULATION 32
3.8 VALIDATION 32
4 MARKET DYNAMICS 33
4.1 OVERVIEW 33
4.2 DRIVERS 34
4.2.1 GROWING DEMAND FOR NEXT-GENERATION ORTHOPEDIC BIOMATERIALS 34
4.2.2 INCREASING OLDER POPULATION LEADING TO INCREASE IN THE PATIENT POPULATION 34
4.2.3 RISING PREVALENCE OF ORTHOPEDIC DISEASES 34
4.3 RESTRAINT 35
4.3.1 LACK OF REIMBURSEMENTS 35
4.3.2 AMBIGUOUS REGULATORY FRAMEWORK 35
4.4 OPPORTUNITY 36
4.4.1 TECHNOLOGICAL ADVANCEMENTS IN THE MEDICAL IMPLANTS MARKET 36
4.4.2 ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS 36
5 MARKET FACTOR ANALYSIS 37
5.1 VALUE CHAIN ANALYSIS 37
5.1.1 R&D AND DESIGNING 38
5.1.2 MANUFACTURING 38
5.1.3 DISTRIBUTION 38
5.1.4 MARKETING AND SALES 38
5.2 PORTER’S FIVE FORCES MODEL 39
5.2.1 THREAT OF NEW ENTRANTS 40
5.2.2 BARGAINING POWER OF SUPPLIERS 40
5.2.3 THREAT OF SUBSTITUTES 40
5.2.4 BARGAINING POWER OF BUYERS 40
5.2.5 INTENSITY OFRIVALRY 40
5.3 COVID-19 IMPACT ANALYSIS 41
5.3.1 IMPACT ON R&D 41
5.3.2 IMPACT ON SUPPLY CHAIN 41
5.3.3 IMPACT ON MANUFACTURERS 41
6 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY PRODUCT 42
6.1 OVERVIEW 42
6.2 RECONSTRUCTIVE JOINT REPLACEMENTS 44
6.2.1 KNEE REPLACEMENT IMPLANTS 45
6.2.2 HIP REPLACEMENT IMPLANTS 46
6.2.3 EXTREMITIES 46
6.3 SPINAL IMPLANTS 47
6.3.1 SPINAL FUSION IMPLANTS 48
6.3.2 VERTEBRAL COMPRESSION FRACTURE (VCF) DEVICES 49
6.3.3 MOTION PRESERVATION DEVICES/NON-FUSION DEVICES 49
6.4 DENTAL IMPLANTS 50
6.4.1 ROOT FORM DENTAL IMPLANTS 51
6.4.2 PLATE FORM DENTAL IMPLANTS 51
6.5 TRAUMA 52
6.6 ORTHOBIOLOGICS 52
6.6.1 VISCOSUPPLEMENTATION 54
6.6.2 DEMINERALIZED BONE MATRIX (DBM) 54
6.6.3 SYNTHETIC BONE SUBSTITUTES 55
6.6.4 BONE MORPHOGENETIC PROTEIN (BMP) 55
6.6.5 ALLOGRAFT 56
7 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY MATERIAL CLASS 57
7.1 OVERVIEW 57
7.2 METAL 58
7.2.1 STAINLESS STEEL 59
7.2.2 TITANIUM ALLOY 59
7.2.3 COBALT ALLOY 60
7.3 NON-METAL 60
7.3.1 CERAMIC 61
- 7.3.1.1 ALUMINA 62
- 7.3.1.2 CALCIUM PHOSPHATE 62
- 7.3.1.3 ZIRCONIUM DIOXIDE 63
- 7.3.1.4 CARBON 63
7.3.2 POLYMERIC 63
- 7.3.2.1 POLYMETHYLMETHACRYLATE (PMMA) 64
- 7.3.2.2 POLYETHYLENE 65
- 7.3.2.3 SILICONE 65
- 7.3.2.4 POLYESTER 65
8 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY APPLICATION 66
8.1 OVERVIEW 66
8.2 JOINT REPLACEMENT 67
8.2.1 HIP REPLACEMENT 68
8.2.2 KNEE REPLACEMENT 68
8.2.3 SHOULDER AND ELBOW REPLACEMENT 69
8.3 FRACTURE FIXATION 69
8.4 TISSUE FIXATION 70
8.5 IMPLANT SURGERY 70
8.6 VISCOSUPPLEMENTATION 71
8.7 OTHERS 71
9 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY END USER 72
9.1 OVERVIEW 72
9.2 HOSPITALS & CLINICS 73
9.3 AMBULATORY SURGICAL CENTERS 73
10 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY REGION 74
10.1 OVERVIEW 74
10.2 AMERICAS 76
10.2.1 NORTH AMERICA 81
- 10.2.1.1 US 87
- 10.2.1.2 CANADA 91
10.2.2 LATIN AMERICA 96
10.3 EUROPE 101
10.3.1 WESTERN EUROPE 106
- 10.3.1.1 GERMANY 112
- 10.3.1.2 FRANCE 117
- 10.3.1.3 UK 122
- 10.3.1.4 ITALY 126
- 10.3.1.5 SPAIN 131
- 10.3.1.6 REST OF WESTERN EUROPE 136
10.3.2 EASTERN EUROPE 141
10.4 ASIA-PACIFIC 146
10.4.1 CHINA 152
10.4.2 JAPAN 157
10.4.3 INDIA 162
10.4.4 AUSTRALIA 167
10.4.5 SOUTH KOREA 172
10.4.6 REST OF ASIA-PACIFIC 177
10.5 MIDDLE EAST & AFRICA 182
10.5.1 MIDDLE EAST 187
10.5.2 AFRICA 192
11 COMPETITIVE LANDSCAPE 197
11.1 OVERVIEW 197
11.2 COMPETITIVE BENCHMARKING 198
11.3 COMPETITOR DASHBOARD 199
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL ORTHOPEDIC BIOMATERIALS MARKET 199
11.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ORTHOPEDIC BIOMATERIALS MARKET 200
11.6 KEY DEVELOPMENT ANALYSIS 200
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 201
11.7.1 PRODUCT LAUNCHES/PRODUCT APPROVALS 201
11.7.2 ACQUISITIONS 202
11.7.3 COLLABORATIONS/JOINT VENTURES 203
11.7.4 EXPANSIONS 203
12 COMPANY PROFILES 204
12.1 STRYKER 204
12.1.1 COMPANY OVERVIEW 204
12.1.2 FINANCIAL OVERVIEW 205
12.1.3 PRODUCTS/SERVICES OFFERED 205
12.1.4 KEY DEVELOPMENTS 206
12.1.5 SWOT ANALYSIS 207
12.1.6 KEY STRATEGIES 207
12.2 COORSTEK INC 208
12.2.1 COMPANY OVERVIEW 208
12.2.2 FINANCIAL OVERVIEW 208
12.2.3 PRODUCTS/SERVICES OFFERED 208
12.2.4 KEY DEVELOPMENTS 209
12.2.5 SWOT ANALYSIS 209
12.2.6 KEY STRATEGIES 209
12.3 ZIMMER BIOMET HOLDINGS INC 210
12.3.1 COMPANY OVERVIEWS 210
12.3.2 FINANCIAL OVERVIEW 210
12.3.3 PRODUCTS/SERVICES OFFERED 211
12.3.4 KEY DEVELOPMENTS 212
12.3.5 SWOT ANALYSIS 213
12.3.6 KEY STRATEGIES 213
12.4 INSTITUT STRAUMANN AG 214
12.4.1 COMPANY OVERVIEW 214
12.4.2 FINANCIAL OVERVIEW 214
12.4.3 PRODUCTS/SERVICES OFFERED 215
12.4.4 KEY DEVELOPMENTS 215
12.4.5 SWOT ANALYSIS 216
12.4.6 KEY STRATEGIES 216
12.5 KYOCERA CORPORATION 217
12.5.1 COMPANY OVERVIEWS 217
12.5.2 FINANCIAL OVERVIEW 217
12.5.3 PRODUCTS/SERVICES OFFERED 218
12.5.4 KEY DEVELOPMENTS 218
12.5.5 SWOT ANALYSIS 218
12.5.6 KEY STRATEGIES 219
12.6 SMITH& NEPHEW 220
12.6.1 COMPANY OVERVIEW 220
12.6.2 FINANCIAL OVERVIEW 220
12.6.3 PRODUCTS/SERVICES OFFERED 221
12.6.4 KEY DEVELOPMENTS 221
12.6.5 SWOT ANALYSIS 222
12.6.6 KEY STRATEGIES 222
12.7 3M 223
12.7.1 COMPANY OVERVIEW 223
12.7.2 FINANCIAL OVERVIEW 224
12.7.3 PRODUCTS/SERVICES OFFERED 225
12.7.4 KEY DEVELOPMENTS 225
12.7.5 SWOT ANALYSIS 226
12.7.6 KEY STRATEGIES 226
12.8 NOBEL BIOCARE HOLDING AG 227
12.8.1 COMPANY OVERVIEW 227
12.8.2 FINANCIAL OVERVIEW 228
12.8.3 PRODUCTS/SERVICES OFFERED 229
12.8.4 KEY DEVELOPMENTS 229
12.8.5 SWOT ANALYSIS 230
12.8.6 KEY STRATEGIES 230
12.9 MEDTRONIC PLC 231
12.9.1 COMPANY OVERVIEW 231
12.9.2 FINANCIAL OVERVIEW 231
12.9.3 PRODUCTS/SERVICES OFFERED 232
12.9.4 KEY DEVELOPMENTS 232
12.9.5 SWOT ANALYSIS 233
12.9.6 KEY STRATEGIES 233
12.10 DEPUY SYNTHES 234
12.10.1 COMPANY OVERVIEW 234
12.10.2 FINANCIAL OVERVIEW 235
12.10.3 PRODUCTS/SERVICES OFFERED 236
12.10.4 KEY DEVELOPMENTS 236
12.10.5 SWOT ANALYSIS 237
12.10.6 KEY STRATEGIES 237
13 APPENDIX 238
13.1 REFERENCES 238
13.2 RELATED REPORTS 238